| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
-Glycosylceramides Enhance the Antitumor Cytotoxicity of Hepatic Lymphocytes Obtained from Cancer Patients by Activating CD3-CD56+ NK Cells In Vitro
*
Department of Research, Japanese Red Cross Central Blood Center, Tokyo, Japan;
Department of Surgery, Division of Surgical Oncology, University of Tokyo, Tokyo, Japan;
Pharmaceutical Research Laboratory, Kirin Brewery, Gunma, Japan; and
§
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461
-Glycosylceramides, such as -galactosylceramide and
-glucosylceramide, induce antitumor immunity in various murine
cancer models. In the murine hepatic metastasis model, V14
TCR+NK1.1+ T cells, which accumulate
preferentially in the liver, are considered to play a key role in the
induction of antitumor immunity by -glycosylceramides. We recently
reported that V24 TCR+ NKT cells, the human homologues
of murine V14 TCR+NK1.1+cells, are rarely
seen among freshly isolated human hepatic lymphocytes. Therefore, it is
important to examine whether -glycosylceramides also enhance the
antitumor cytotoxicity of human hepatic lymphocytes, as they have been
shown to do in murine systems, to determine the usefulness of
-glycosylceramides in cancer immunotherapy in humans. Here, we show
that -glycosylceramides greatly enhance the cytotoxicity of human
hepatic lymphocytes obtained from cancer patients against the tumor
cell lines, K562 and Colo201, in vitro. The direct effector cells of
the elicited cytotoxicity were CD3-CD56+ NK
cells. Even though V24 TCR+NKT cells proliferated
remarkably in response to -glycosylceramides, they did not
contribute directly to the cytotoxicity. Our observations strongly
suggest the potential usefulness of -glycosylceramides for
immunotherapy of liver cancer in humans based on their ability to
activate CD3-CD56+ NK cells in the
liver.
This article has been cited by other articles:
|
|
 |
|
  K. Azakami, T. Sato, N. Araya, A. Utsunomiya, R. Kubota, K. Suzuki, D. Hasegawa, T. Izumi, H. Fujita, S. Aratani, et al. Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders Blood, October 8, 2009; 114(15): 3208 - 3215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bricard, V. Cesson, E. Devevre, H. Bouzourene, C. Barbey, N. Rufer, J. S. Im, P. M. Alves, O. Martinet, N. Halkic, et al. Enrichment of Human CD4+ V{alpha}24/V{beta}11 Invariant NKT Cells in Intrahepatic Malignant Tumors J. Immunol., April 15, 2009; 182(8): 5140 - 5151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Crough, M. Nieda, and A. J. Nicol Granulocyte Colony-Stimulating Factor Modulates {alpha}-Galactosylceramide-Responsive Human V{alpha}24+V{beta}11+ NKT Cells J. Immunol., October 15, 2004; 173(8): 4960 - 4966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Durante-Mangoni, R. Wang, A. Shaulov, Q. He, I. Nasser, N. Afdhal, M. J. Koziel, and M. A. Exley Hepatic CD1d Expression in Hepatitis C Virus Infection and Recognition by Resident Proinflammatory CD1d-Reactive T Cells J. Immunol., August 1, 2004; 173(3): 2159 - 2166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sun, Z. Tian, S. Kulkarni, and B. Gao IL-6 Prevents T Cell-Mediated Hepatitis via Inhibition of NKT Cells in CD4+ T Cell- and STAT3-Dependent Manners J. Immunol., May 1, 2004; 172(9): 5648 - 5655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kenna, L. G. Mason, S. A. Porcelli, Y. Koezuka, J. E. Hegarty, C. O'Farrelly, and D. G. Doherty NKT Cells from Normal and Tumor-Bearing Human Livers Are Phenotypically and Functionally Distinct from Murine NKT Cells J. Immunol., August 15, 2003; 171(4): 1775 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Giaccone, C. J. A. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. M. E. von Blomberg, R. J. Scheper, H. J. J. van der Vliet, A. J. M. van den Eertwegh, et al. A Phase I Study of the Natural Killer T-Cell Ligand {alpha}-Galactosylceramide (KRN7000) in Patients with Solid Tumors Clin. Cancer Res., December 1, 2002; 8(12): 3702 - 3709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Gumperz, S. Miyake, T. Yamamura, and M. B. Brenner Functionally Distinct Subsets of CD1d-restricted Natural Killer T Cells Revealed by CD1d Tetramer Staining J. Exp. Med., March 4, 2002; 195(5): 625 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Exley, Q. He, O. Cheng, R.-J. Wang, C. P. Cheney, S. P. Balk, and M. J. Koziel Cutting Edge: Compartmentalization of Th1-Like Noninvariant CD1d-Reactive T Cells in Hepatitis C Virus-Infected Liver J. Immunol., February 15, 2002; 168(4): 1519 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Metelitsa, O. V. Naidenko, A. Kant, H.-W. Wu, M. J. Loza, B. Perussia, M. Kronenberg, and R. C. Seeger Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells J. Immunol., September 15, 2001; 167(6): 3114 - 3122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Karadimitris, S. Gadola, M. Altamirano, D. Brown, A. Woolfson, P. Klenerman, J.-L. Chen, Y. Koezuka, I. A. G. Roberts, D. A. Price, et al. From the Cover: Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography PNAS, March 13, 2001; 98(6): 3294 - 3298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yu, M. Hagihara, K. Ando, B. Gansuvd, H. Matsuzawa, T. Tsuchiya, Y. Ueda, H. Inoue, T. Hotta, and S. Kato Enhancement of Human Cord Blood CD34+ Cell-Derived NK Cell Cytotoxicity by Dendritic Cells J. Immunol., February 1, 2001; 166(3): 1590 - 1600. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
